Lemborexant as a potential pharmacotherapy for the treatment of CUD

Exclusion criteria:

- Known allergies or hypersensitivities to Lemborexant
- Currently undergoing evidence-based, professionally guided treatment for CUD or history of treatment within 30 days before enrollment or currently seeking immediate treatment.
- Current or recent (within the past 12 weeks) participation in a clinical trial involving medication administration.
- Moderate to severe hepatic (liver) impairment.
- Past or ongoing moderate to severe psychiatric disorders
- Active suicidal ideation or serious attempt within the past 3 years.
- Moderate to severe alcohol or substance use disorder (other than cannabis or nicotine) in the past 12 months.
- Complex sleep behaviors, sleep apnea, restless leg syndrome, and Periodic Limb Movement Disorder.
- Epilepsy or history of seizures.
- Cognitive impairment
- Blood pressure over 160/95mmHg.
- Use of any Orexin-Antagonist in the past 3 months.
- Current pregnancy or nursing, trying to become pregnant, or unwilling to use acceptable method of contraception during the study. Acceptable methods of contraception include oral contraceptives, barrier with spermicide, IUD, medroxyprogesterone acetate (Depo Provera), contraceptive patch, vaginal contraceptive ring, or being post-menopausal or deemed medically unable to become pregnant (i.e., due to hysterectomy).
- Any hospitalization or emergency department visit related to cannabis use.